Advisornet Financial’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Advisornet Financial’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-667	Closed	-$18K	–	2200
2022 Q1	$18K	Hold	667	–	–	﹤0.01%	1290
2021 Q4	$24K	Hold	667	–	–	﹤0.01%	1251
2021 Q3	$27K	Hold	667	–	–	﹤0.01%	1180
2021 Q2	$27K	Hold	667	–	–	﹤0.01%	1161
2021 Q1	$24K	Hold	667	–	–	﹤0.01%	1151
2020 Q4	$21K	Buy	+667	New	+$20.3K	﹤0.01%	1123

Other funds holding GERM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Advisornet Financial's GERM Position: Q2 2022 in Review

Advisornet Financial sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q2 2022, closing a stake of 667 shares — an estimated $18K sold.

Advisornet Financial first reported a position in GERM in Q4 2020 and held it in 6 quarters. The position peaked at $27K in Q3 2021. 25 funds tracked by Wall St. Rank hold GERM as of Q2 2022.

Advisornet Financial reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q2 2022 after selling out during the quarter.
Advisornet Financial sold 667 Amplify Treatments, Testing and Advancements ETF shares in Q2 2022, an estimated $18K.
Advisornet Financial first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2020 and held it in 6 quarters.
Advisornet Financial's Amplify Treatments, Testing and Advancements ETF position peaked at $27K in Q3 2021.
25 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q2 2022.

Based on Advisornet Financial's 13F filing for Q2 2022, filed 7 Jul 2022.